Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.64 |
| ▸ | AHR | P35869 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19744020 | 0.86 | KDM4E (0.68) | PLK1KDM4EAHRLMNAMAOB | |
| SCHEMBL27818818 | 0.83 | KDM4E (0.64) | PLK1KDM4EAHRLMNAMAOB | |
| SCHEMBL754304 | 0.82 | KDM4E (0.63) | PLK1KDM4EAHRLMNAMAOB | |
| SCHEMBL5567052 | 0.81 | LMNA (0.64) | PLK1KDM4EAHRLMNAMAOB | |
| SCHEMBL719242 | 0.81 | KDM4E (0.78) | PLK1KDM4EAHRLMNAMAPT | |
| SCHEMBL11312503 | 0.80 | PLK1 (0.64) | PLK1KDM4EAHRLMNAMAOB | |
| SCHEMBL6964091 | 0.80 | KDM4E (0.71) | PLK1KDM4EAHRLMNAMAPT | |
| SCHEMBL4775716 | 0.80 | KDM4E (0.71) | PLK1KDM4EAHRLMNAMAPT | |
| SCHEMBL10007069 | 0.79 | PLK1 (1.00) | PLK1KDM4EAHRLMNAMAPT | |
| SCHEMBL585270 | 0.78 | KDM4E (1.00) | PLK1KDM4EAHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603912-B1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-18 | — | — | EP | disclosed |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1460070-B1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS CH (CH) | 2007-05-16 | — | — | EP | disclosed |
| US-20070037823-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037823-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20060276485-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-12-07 | — | — | US | disclosed |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-10-26 | — | — | US | disclosed |
| EP-1606278-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1606281-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1603911-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603912-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| EP-1468999-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004083199-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083208-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083209-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083198-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| EP-1460069-A1 | Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
| EP-1460073-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
| EP-1460070-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037823-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | PLK1 2748/4885KDM4E 158/4885AHR 339/4885 |
| US-20060276485-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | PLK1 2771/4885KDM4E 165/4885AHR 326/4885 |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | PLK1 3533/4885KDM4E 163/4885AHR 176/4885 |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | PLK1 2771/4885KDM4E 165/4885AHR 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.